Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature

Filippo Alongi, Stefano Arcangeli, Berardino De Bari, Niccolò Giaj-Levra, Alba Fiorentino, Rosario Mazzola, Marco Trovò

Research output: Contribution to journalReview article

Abstract

Small cell lung cancer (SCLC) is relative rare histology in lung cancer patients. The standard treatment, in patients with an intra-thoracic disease, is represented by the use of concurrent chemo-radiotherapy; while patients with early SCLC stage, surgical resection could be recommended. Stereotactic body radiotherapy (SBRT) is a recently introduced technique allowing the delivery of very high radiation doses to limited target volumes and it is considered the standard approach in the treatment of not operable stage I Non Small-Cell Lung Cancer (NSCLC). The successful role option of SBRT in early NSCLC in terms of local control and toxicity profile opened the issue in the use of this approach in early stage small cell lung cancer (SCLC). Aim of this review is to discuss the current literature in the safety and efficacy of SBRT in the treatment of patients with stage I SCLC.

Original languageEnglish
Pages (from-to)67-71
Number of pages5
JournalCritical Reviews in Oncology/Hematology
Volume112
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Small Cell Lung Carcinoma
Radiosurgery
Radiotherapy
Non-Small Cell Lung Carcinoma
Thoracic Diseases
Lung Neoplasms
Histology
Therapeutics
Radiation
Safety

Keywords

  • Outcomes
  • Small cell lung cancer
  • Stereotactic ablative radiotherapy
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Geriatrics and Gerontology

Cite this

Stage-I small cell lung cancer : A new potential option for stereotactic ablative radiation therapy? A review of literature. / Alongi, Filippo; Arcangeli, Stefano; De Bari, Berardino; Giaj-Levra, Niccolò; Fiorentino, Alba; Mazzola, Rosario; Trovò, Marco.

In: Critical Reviews in Oncology/Hematology, Vol. 112, 01.04.2017, p. 67-71.

Research output: Contribution to journalReview article

Alongi, Filippo ; Arcangeli, Stefano ; De Bari, Berardino ; Giaj-Levra, Niccolò ; Fiorentino, Alba ; Mazzola, Rosario ; Trovò, Marco. / Stage-I small cell lung cancer : A new potential option for stereotactic ablative radiation therapy? A review of literature. In: Critical Reviews in Oncology/Hematology. 2017 ; Vol. 112. pp. 67-71.
@article{47185045b505430892c62ad670bd9f38,
title = "Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature",
abstract = "Small cell lung cancer (SCLC) is relative rare histology in lung cancer patients. The standard treatment, in patients with an intra-thoracic disease, is represented by the use of concurrent chemo-radiotherapy; while patients with early SCLC stage, surgical resection could be recommended. Stereotactic body radiotherapy (SBRT) is a recently introduced technique allowing the delivery of very high radiation doses to limited target volumes and it is considered the standard approach in the treatment of not operable stage I Non Small-Cell Lung Cancer (NSCLC). The successful role option of SBRT in early NSCLC in terms of local control and toxicity profile opened the issue in the use of this approach in early stage small cell lung cancer (SCLC). Aim of this review is to discuss the current literature in the safety and efficacy of SBRT in the treatment of patients with stage I SCLC.",
keywords = "Outcomes, Small cell lung cancer, Stereotactic ablative radiotherapy, Toxicity",
author = "Filippo Alongi and Stefano Arcangeli and {De Bari}, Berardino and Niccol{\`o} Giaj-Levra and Alba Fiorentino and Rosario Mazzola and Marco Trov{\`o}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.critrevonc.2017.02.010",
language = "English",
volume = "112",
pages = "67--71",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Stage-I small cell lung cancer

T2 - A new potential option for stereotactic ablative radiation therapy? A review of literature

AU - Alongi, Filippo

AU - Arcangeli, Stefano

AU - De Bari, Berardino

AU - Giaj-Levra, Niccolò

AU - Fiorentino, Alba

AU - Mazzola, Rosario

AU - Trovò, Marco

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Small cell lung cancer (SCLC) is relative rare histology in lung cancer patients. The standard treatment, in patients with an intra-thoracic disease, is represented by the use of concurrent chemo-radiotherapy; while patients with early SCLC stage, surgical resection could be recommended. Stereotactic body radiotherapy (SBRT) is a recently introduced technique allowing the delivery of very high radiation doses to limited target volumes and it is considered the standard approach in the treatment of not operable stage I Non Small-Cell Lung Cancer (NSCLC). The successful role option of SBRT in early NSCLC in terms of local control and toxicity profile opened the issue in the use of this approach in early stage small cell lung cancer (SCLC). Aim of this review is to discuss the current literature in the safety and efficacy of SBRT in the treatment of patients with stage I SCLC.

AB - Small cell lung cancer (SCLC) is relative rare histology in lung cancer patients. The standard treatment, in patients with an intra-thoracic disease, is represented by the use of concurrent chemo-radiotherapy; while patients with early SCLC stage, surgical resection could be recommended. Stereotactic body radiotherapy (SBRT) is a recently introduced technique allowing the delivery of very high radiation doses to limited target volumes and it is considered the standard approach in the treatment of not operable stage I Non Small-Cell Lung Cancer (NSCLC). The successful role option of SBRT in early NSCLC in terms of local control and toxicity profile opened the issue in the use of this approach in early stage small cell lung cancer (SCLC). Aim of this review is to discuss the current literature in the safety and efficacy of SBRT in the treatment of patients with stage I SCLC.

KW - Outcomes

KW - Small cell lung cancer

KW - Stereotactic ablative radiotherapy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=85015664635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015664635&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2017.02.010

DO - 10.1016/j.critrevonc.2017.02.010

M3 - Review article

C2 - 28325266

AN - SCOPUS:85015664635

VL - 112

SP - 67

EP - 71

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -